Amgen settles Prolia patent suit with Celltrion, teeing up potential biosimilar launch in June

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term competition thanks to a new agreement between Amgen and Celltrion.

Late last week, Amgen said it had reached a settlement with Celltrion, putting a bout of patent litigation to bed and allowing the South Korean company to launch its biosimilar versions of Amgen’s bone blockbusters Prolia and Xgeva (denosumab) as early as June 1.